Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657947 | 0.92 | ALOX5 (0.44) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL657946 | 0.92 | ALOX5 (0.44) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL1246039 | 0.85 | ALOX5 (0.39) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL2030947 | 0.83 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL2030946 | 0.83 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL658527 | 0.82 | ALOX5 (0.40) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL12557266 | 0.82 | ALOX5 (0.49) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL12557162 | 0.82 | ALOX5 (0.49) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL12557192 | 0.82 | ALOX5 (0.49) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 | |
| SCHEMBL12557211 | 0.78 | ALOX5 (0.43) | ALOX5TBXA2RPTGFRPTGER2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889894-B2 | Compounds for use in therapy | BANGOR UNIVERSITY (GB) | 2014-11-18 | — | — | US | disclosed |
| US-8728515-B2 | Adjuvants for use in vaccination | BANGOR UNIVERSITY (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2620158-A1 | Adjuvants for use in vaccination | Bangor University (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20110150981-A1 | Compounds for Use in Therapy | BANGOR UNIVERSITY (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | BANGOR UNIVERSITY (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-2278995-A2 | COMPOUNDS FOR USE IN THERAPY | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2278996-A1 | ADJUVANTS FOR USE IN VACCINATION | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009130506-A2 | COMPOUNDS FOR USE IN THERAPY | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130508-A1 | ADJUVANTS FOR USE IN VACCINATION | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142916-A1 | Adjuvants for Use in Vaccination | NR1H3, NR1H2, INTS6 | ALOX5 663/4885TBXA2R 1770/4885PTGFR 4566/4885 |
| US-20110150981-A1 | Compounds for Use in Therapy | CD4, MSR1, TST | ALOX5 186/4885TBXA2R 887/4885PTGFR 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.